Thursday, February 2, 2017

Nature Reviews Drug Discovery contents February 2017 Volume 16 Number 2 pp 71-147

If you are unable to see the message below, click here to view.

Nature Reviews Drug Discovery

February 2017 Volume 16 Number 2Advertisement
Nature Reviews Drug Discovery cover
2015 2-year Impact Factor 47.120 Journal Metrics 2-year Median 31
In this issue
News and Analysis
Research Highlights

Also this month
 Featured article:
Cornerstones of CRISPR–Cas in drug discovery and therapy
Christof Fellmann, Benjamin G. Gowen, Pei-Chun Lin, Jennifer A. Doudna & Jacob E. Corn

Genomics has met its match! 


Explore the relationship between genotype and phenotype with Metabolon's revolutionary solutions. We turn data into actionable insight unlocking the full potential of the genome. See why genomics and metabolomics are better together.

Download our eBook 

Recommend to library
Unexplored opportunities in the druggable human genome

This poster presents a categorization of human proteins based on the amount of data on them, highlighting a knowledge deficit and indicating novel drug discovery opportunities. 

Download the Poster free online

Produced with support from:

Illuminating the Druggable Genome Knowledge Management Center 

BioPharma DealmakersCompany Profiles and Partnering Opportunities

A new open access journal dedicated to publishing the most important scientific advances in all aspects of genomics and its application in the practice of medicine.

Part of the Nature Partner Journals series, the journal is published in partnership with the Center of Excellence in Genomic Medicine Research.

Open for submissions >>
Comment: Strategies for delivering value from digital technology transformation
Eric D. Perakslis
p71 | doi:10.1038/nrd.2016.265
Many organizations are attempting to harness emerging digital technologies and the surge in the amount of health-related data to drive advances in the development and use of medicines. Focusing on just a few well-proven and readily available strategies could enable such organizations to quickly realize greater value from data and digital technologies.
Full Text | PDF

2016 FDA drug approvals
Asher Mullard
p73 | doi:10.1038/nrd.2017.14
FDA approval count fell last year, despite a steady regulatory filing rate.
2016 EMA drug approval recommendations
Asher Mullard
p77 | doi:10.1038/nrd.2017.17
FDA approves splice-modulating drug
Asher Mullard
p77 | doi:10.1038/nrd.2017.18
Cancer reproducibility project yields first results
Asher Mullard
p77 | doi:10.1038/nrd.2017.19
Ebola vaccine success
Asher Mullard
p77 | doi:10.1038/nrd.2017.20
Market watch: Value of 2016 FDA drug approvals: reversion to the mean?
Ulrik Schulze, Michael Ringel, Valery Panier & Mathias Baedeker
p78 | doi:10.1038/nrd.2017.8
Regulatory watch: Outcomes of early health technology assessment dialogues in medicinal product development
Francois Maignen, Leeza Osipenko, Pilar Pinilla-Dominguez & Emily Crowe
p79 | doi:10.1038/nrd.2016.286
John Jenkins
p80 | doi:10.1038/nrd.2017.2
John Jenkins, former Director of the FDA's Office of New Drugs, discusses approvals standards, breakthrough therapy designation and regulatory science hurdles.
The immuno-oncology race: myths and emerging realities
Stephen Cavnar, Pedro Valencia, Jesse Brock, Judith Wallenstein & Valery Panier
p83 | doi:10.1038/nrd.2016.279
This article analyses the huge volume of clinical trial activity for immune checkpoint inhibitors, and discusses the development of the market and strategic trends for immuno-oncology therapies in general.

Genetic disorders: Steps towards epigenetic therapy for PWS
p85 | doi:10.1038/nrd.2017.3

Autoimmune diseases: Inhibitor of adaptor protein shows self-antigen selectivity
p86 | doi:10.1038/nrd.2017.5

Receptor pharmacology: Picking the pocketome for orphan receptor ligands
p86 | doi:10.1038/nrd.2017.6

Cancer: Tumour vessel normalization takes centre stage
p87 | doi:10.1038/nrd.2017.4

Anticancer drugs: The fat controller
p88 | doi:10.1038/nrd.2017.7


Alzheimer disease: Identification of novel Aβ inhibitors | Neurodegenerative disease: Pituitary adenylate cyclase activator ameliorates SBMA | HIV: CRISPR screen identifies novel therapeutic targets | Epilepsy: HSP90 inhibition suppresses seizures

Drug Discovery
JOBS of the week
Research Resource Director
Weill Cornell Medicine
Postdoctoral Position at USC
University of Southern California
Duke and NCCU Postdoctoral Fellowship in Translational Cancer Disparties Research
Duke Cancer Institute
Doctoral Students in Molecular Medicine
Institute for Molecular Medicine Finland (FIMM)
Post Doc - Department of Pathology
Thomas Jefferson University (TJU)
More Science jobs from
Drug Discovery
9th Ocular Diseases Drug Discovery Conference
San Diego, USA
More science events from
Nature Outlook: Precision Medicine

Health care that is tailored on the basis of an individual's genes, lifestyle or environment, is not a modern concept. But advances in genetics and the growing availability of health data for researchers and physicians promise to make this new era of medicine more personalized than ever before.

Access the Outlook free online

Sponsored by:
Illumina, Inc.
Cornerstones of CRISPR–Cas in drug discovery and therapy
Christof Fellmann, Benjamin G. Gowen, Pei-Chun Lin, Jennifer A. Doudna & Jacob E. Corn
p89 | doi:10.1038/nrd.2016.238
The use of CRISPR–Cas technology for gene editing has rapidly become widespread. Here, Corn and colleagues discuss the applications of this revolutionary tool in drug discovery and development, describing how it could make substantial contributions to target identification and validation, animal models and cell-based therapies.
Abstract | Full Text | PDF | Supplementary information

Induced protein degradation: an emerging drug discovery paradigm
Ashton C. Lai & Craig M. Crews
p101 | doi:10.1038/nrd.2016.211
Small-molecule drug discovery has traditionally focused on occupancy of a binding site that directly affects protein function. This article discusses emerging technologies, such as proteolysis-targeting chimaeras (PROTACs), that exploit cellular quality control machinery to selectively degrade target proteins, which could have advantages over traditional approaches, including the potential to target proteins that are not currently therapeutically tractable.
Abstract | Full Text | PDF

Induced pluripotent stem cell technology: a decade of progress
Yanhong Shi, Haruhisa Inoue, Joseph C. Wu & Shinya Yamanaka
p115 | doi:10.1038/nrd.2016.245
Since the advent of induced pluripotent stem cell (iPSC) technology a decade ago, human iPSCs have been widely used for disease modelling, drug discovery and cell therapy development. This article discusses progress in applications of iPSC technology that are particularly relevant to drug discovery and regenerative medicine, including the powerful combination of human iPSC technology with recent developments in gene editing.
Abstract | Full Text | PDF

DNA-encoded chemistry: enabling the deeper sampling of chemical space
Robert A. Goodnow, Jr, Christoph E. Dumelin & Anthony D. Keefe
p131 | doi:10.1038/nrd.2016.213
DNA-encoded chemistry enables rapid and inexpensive syntheses and screening of vast chemical libraries, and is generating substantial interest and investment in the pharmaceutical industry. Here, Goodnow and colleagues provide an overview of the steps involved in the generation of DNA-encoded libraries, highlighting key applications and future directions for this technology.
Abstract | Full Text | PDF

Poster on Molecular mechanisms of amyotrophic lateral sclerosis

This poster from Nature Reviews Neuroscience provides an overview of the molecular and cellular mechanisms that have been proposed to contribute to the pathogenesis of amyotrophic lateral sclerosis, which is the most common form of motor neuron disease. 

Download free online
Funded by a grant from MT Pharma America, Inc
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on For event advertising opportunities across the Nature Publishing Group portfolio please contact
More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your account at:
(You will need to log in to be recognised as a registrant).

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our feedback department

Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2017 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.

nature publishing group

No comments: